NCT07076446View on ClinicalTrials.gov

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

PHASE4RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

May 4, 2026

Study Completion Date

May 4, 2026

Conditions
Primary Immunodeficiency
Interventions
BIOLOGICAL

IgPro

IgPro20 is a solution for infusion for subcutaneous administration.

Trial Locations (5)

15241

RECRUITING

84000884 - Allergy & Clinical Immunology, Pittsburgh

55446

RECRUITING

84000918 - Midwest Immunology, Plymouth

73120

RECRUITING

84000885 - Allergy, Asthma and Clinical Research Center, Oklahoma City

80112

RECRUITING

84000910 - Immunoe Health Centers, Centennial

85340

RECRUITING

84000890 - Research Solutions of AZ, Litchfield Park

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT07076446 - An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) | Biotech Hunter | Biotech Hunter